Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
AstraZeneca, the UK pharmaceuticals company, has lined up $17.5bn of bridge loans from three banks to back its $39bn acquisition of US biotech firm Alexion. -
Chinese healthcare technology company Yidu Tech is set to begin drumming up demand for its Hong Kong IPO after winning listing approval from the city’s bourse.
-
Ukraine, which has proven itself a favourite of emerging market investors this year, has slipped into international markets for a small dollar tap before year-end. The trade comes amid strained negotiations between Ukraine and the IMF over the disbursement of emergency funding.
-
The European Banking Authority has updated the market on how it thinks Basel IV will impact bank capital requirements, setting the scene for another paper next week examining how the rules could interact with the economic shock of the coronavirus pandemic.
-
CVS Health Corp jumped at the opportunity to conduct a liability management exercise this week, as US corporate bond issuance began to tail off amid signs of investor caution in the run-up to the year’s end.
-
Qiagen, the Dutch diagnostics company, has launched the sale of a new convertible bond to refinance the unwinding of an older bond, set to mature in 2021.
